El nostre pipeline
Última actualizació, juliol 2022.
|
Molecule /
Project
|
Indication
|
Expected Launch
|
Preclinical Phase | Phase I | Phase II | Phase III | Under Registration | Geography |
|---|---|---|---|---|---|---|---|---|
| Lebrikizumab* | Atopic dermatitis |
Late 2023
|
EU
|
|||||
| Klisyri® (extended label) | Actinic keratosis |
US 2024 / EU 2025
|
U.S.
EU
|
|||||
| Sarecycline | Acne |
2024
|
China
|
|||||
| Efinaconazole | Onychomycosis |
2023
|
EU
|
|||||
| Anti-IL-1RAP | Autoinmune dermatology |
TBC
|
|
* Working with US partner Eli Lilly to decide the best pathway with phase 3b trial that suits US and EU needs.